Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 13Neoplasms 8Breast Neoplasms 7Neoplasm Metastasis 5Prostatic Neoplasms 4Pancreatic Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Urogenital Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Solid Tumor 1Sarcoma, Ewing 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Ovarian Diseases 1Osteosarcoma 1Neuroblastoma 1Neoplasm, Residual 1Melanoma 1Lung Neoplasms 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1HER2-negative Metastatic Breast Cancer 1Gonadal Disorders 1Genital Neoplasms, Male 1Genital Neoplasms, Female 1Genital Diseases, Male 1Genital Diseases, Female 1

Interventions

Gemcitabine 20Cisplatin 17pembrolizumab 11Magnetic Resonance Spectroscopy 7durvalumab 5Platinum 5Irinotecan 5Fluorouracil 51,2-diaminocyclohexaneplatinum II citrate 5Leucovorin 4Taxes 3Oxaliplatin 3Nivolumab 3Fluorodeoxyglucose F18 3Carboplatin 3Biopsy 3Bevacizumab 3spartalizumab 2pemigatinib 2ivosidenib 2fludarabine 2budigalimab 2atezolizumab 2Specimen Handling 2Radiosurgery 2Paclitaxel 2Immunoglobulin G 2Floxuridine 2FAPI-46 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cholangiocarcinoma × niraparib × Clear all
NCT04764084 2021-02-21

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Peking University Cancer Hospital & Institute

Phase 1 Unknown
52 enrolled
BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡